112 related articles for article (PubMed ID: 8845326)
1. Does dexamethasone leucocytosis facilitate full dosage adjuvant chemotherapy for breast cancer?
Rees GJ
Clin Oncol (R Coll Radiol); 1995; 7(4):257-8. PubMed ID: 8845326
[TBL] [Abstract][Full Text] [Related]
2. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
3. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
5. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
[TBL] [Abstract][Full Text] [Related]
8. High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
Gez E; Goodman S; Isacson R; Gerra C; Sulkes A
Oncology; 1986; 43(3):173-5. PubMed ID: 3754627
[TBL] [Abstract][Full Text] [Related]
9. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients.
Watanabe T
Cancer Chemother Pharmacol; 1998; 42 Suppl():S68-70. PubMed ID: 9750032
[TBL] [Abstract][Full Text] [Related]
12. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
13. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
14. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
16. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
Faul C; Brufsky A; Gerszten K; Flickinger J; Kunschner A; Jacob H; Vogel V
Eur J Cancer; 2003 Apr; 39(6):763-8. PubMed ID: 12651201
[TBL] [Abstract][Full Text] [Related]
17. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
18. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
Ferretti G; Lopez M; Terzoli E; Cortesi E; Antimi M; Marolla P; Giannarelli D; Cognetti F; Papaldo P
J Clin Oncol; 2006 Dec; 24(35):5618-9. PubMed ID: 17158554
[No Abstract] [Full Text] [Related]
19. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
20. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
